Marked. - Issue 059
Apple faces a $5.7 billion haptics verdict, while Mylan opens a new Wegovy patent front.
Issue No. 059
September 28, 2026
New York
|
|
|
|
|
|
|
|
The IP Briefing · by ESCA Legal
|
|
|
|
| A federal jury in San Diego awarded Taction Technology more than $5.7 billion after finding that Apple's Taptic Engine infringed claims from two haptics patents used in iPhones and Apple Watches. |
| § | The patents cover vibration-based tactile transducer technology that lets users feel a device respond to input. | | § | The case returned to trial after the Federal Circuit revived it following an earlier dismissal. | | § | The jury found infringement but did not find that Apple acted willfully. | | § | Apple disputes both infringement and the damages award and says it will appeal. |
|
| Continue reading → |
| § ESCA Takeaway |
| This issue pairs a jury verdict involving everyday device feedback with a new dispute over a blockbuster medicine. Both stories show how narrow patent claims can carry consequences across products used by millions of consumers. |
|
|
| More IP Stories |
|
| § Patent · Filed |
|
|
| Mylan Pharmaceuticals filed a Delaware federal lawsuit seeking a declaration that its proposed generic version of Novo Nordisk's Wegovy does not infringe a patent covering administration through a single-dose pen. |
| § | The case concerns Mylan's proposed generic version of the weight-loss medicine semaglutide. | | § | Mylan asks the court for a noninfringement declaration covering U.S. Patent No. 12,275,786. | | § | The filing adds a new patent to a broader dispute between the companies over proposed Wegovy generics. | | § | The complaint was filed in the U.S. District Court for the District of Delaware. |
|
|
Why it matters
The case connects patent scope to competition around one of the most recognizable weight-loss medicines in the United States. It also adds another claim set to an already active generic-drug dispute.
|
| Continue reading → |
|
|
|
|
|
|
Not subscribed? Sign up for future editions of Marked by ESCA Legal.
|
|
|
|
This newsletter is for informational purposes only and does not constitute legal advice. Published by ESCA Legal. Reading it does not create an attorney-client relationship. Attorney advertising; prior results do not guarantee a similar outcome.
|
|